Compare BCHT & NNVC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BCHT | NNVC |
|---|---|---|
| Founded | N/A | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.6M | 35.2M |
| IPO Year | 2016 | 2008 |
| Metric | BCHT | NNVC |
|---|---|---|
| Price | $1.38 | $1.02 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $15.00 | N/A |
| AVG Volume (30 Days) | 68.3K | ★ 261.9K |
| Earning Date | 05-13-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 10.00 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $17,626,366.00 | N/A |
| Revenue This Year | $13.42 | N/A |
| Revenue Next Year | $61.22 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 1.26 | N/A |
| 52 Week Low | $1.14 | $0.85 |
| 52 Week High | $2.48 | $2.23 |
| Indicator | BCHT | NNVC |
|---|---|---|
| Relative Strength Index (RSI) | 51.97 | 19.26 |
| Support Level | $1.26 | $0.86 |
| Resistance Level | $1.54 | $1.07 |
| Average True Range (ATR) | 0.07 | 0.06 |
| MACD | 0.02 | -0.02 |
| Stochastic Oscillator | 75.00 | 2.26 |
Birchtech Corp is a provider of specialty activated carbon technologies, delivering solutions for air and water purification. It provides patented and proprietary Sorbent Enhancement Additive (SEA) technologies for mercury emissions capture to the coal-fired utility sector, and is developing water purification technologies with a specialization on forever chemicals such as PFAS and PFOS. Geographically, the company derives all of its revenue from the United States.
Nanoviricides Inc is a nano-biopharmaceutical company that is engaged in discovering, developing, and commercializing therapeutics to advance the care of patients suffering from life-threatening viral infections. The company engaged in the application of nanomedicine technologies to the complex issues of viral diseases. It focuses its research and clinical programs on specific anti-viral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs and through in-licensing.